Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 23INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasms 1Keratosis, Actinic 1Heart Failure 1Gastrointestinal Neoplasms 1Disease 1Colorectal Neoplasms 1Breast Neoplasms 1Biliary Tract Neoplasms 1Arrhythmias, Cardiac 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 65Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 30Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Rituximab 22Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Control Groups × Clear all
NCT06092606 2023-10-23

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

Monyan Pharmaceutical (Shanghai) Co., Ltd.

Phase 2 Unknown
90 enrolled

Arrhythmias, Cardiac, Heart Failure, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡